EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the closing of a public offering of 5,122,273 shares of common stock, including 1,095,000 shares purchased under the underwriter's option. The shares were priced at $13.75 each, with pre-funded warrants sold for $13.74 each, generating gross proceeds of approximately $115.4 million. The proceeds will support the Phase 2 clinical trials of EYP-1901 for wet AMD, DR, and RVO, along with earlier-stage pipeline initiatives. The offering was made under an SEC shelf registration statement.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced an underwritten public offering of 4,027,273 shares at $13.75 each, alongside pre-funded warrants for 3,272,727 shares at $13.74 each, aiming for gross proceeds of approximately $100.3 million. The funds will primarily advance EYP-1901 into Phase 2 trials for wet AMD, DR, and RVO, and support pipeline initiatives. The offering is expected to close by November 19, 2021, pending customary conditions.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced an underwritten public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. The offering aims to fund Phase 2 clinical trials for EYP-1901, targeting wet AMD, diabetic retinopathy, and retinal vein occlusion. The proceeds will also support earlier stage pipeline initiatives and general corporate purposes. The securities are offered under a previously filed registration statement, and the offering's completion is subject to market conditions.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced promising six-month interim data from its Phase 1 DAVIO clinical trial of EYP-1901, an investigational treatment for wet age-related macular degeneration (wet AMD). The trial demonstrated a favorable safety profile with no ocular serious adverse events and a 79% reduction in treatment burden. Notably, 76% and 53% of patients did not require rescue treatments up to four and six months, respectively. EyePoint plans to initiate a Phase 2 trial in 2022 and has a Type C meeting with the FDA scheduled for December 1, 2021, to discuss registration trials.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced encouraging six-month interim data from its Phase 1 DAVIO clinical trial of EYP-1901, an anti-VEGF treatment for wet age-related macular degeneration (AMD). Presented at the AAO 2021 Meeting, the trial involved 17 patients, showcasing a 79% reduction in treatment burden and no serious adverse events reported. Patients experienced sustained visual acuity with 76% and 53% not needing rescue therapy after four and six months, respectively. EyePoint plans to advance EYP-1901 into Phase 2 trials in 2022 and engage with the FDA regarding registration trials.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will have CEO Nancy Lurker present at two virtual conferences: the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET and the 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. The company focuses on developing therapeutics for serious eye disorders, including its Durasert® technology. Webcasts of the presentations will be available on their website, with replays accessible for 30 and 90 days, respectively.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on November 13 at 12:00 P.M. ET to discuss interim data from its Phase 1 DAVIO trial of EYP-1901, aimed at treating wet AMD. The interim results will be presented by Dr. David Boyer during the AAO Retina Subspecialty Day. EYP-1901 is designed for sustained drug delivery through the company's proprietary Durasert technology, which may provide a twice-yearly treatment option for patients. The event will be accessible via phone and webcast on the company's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported its Q3 2021 financial results, highlighting a 49% increase in net product revenue, totaling $8.6 million compared to $5.8 million in the same quarter last year. The Company presented positive safety data from the Phase 1 DAVIO trial for EYP-1901 targeting wet AMD at the ASRS 2021 Annual Meeting. Operating expenses rose to $24.4 million, leading to a net loss of $16.7 million or ($0.58) per share. However, cash reserves improved to $119.7 million, supporting operations through 2022.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Dr. Jay S. Duker as Chief Operating Officer, expanding his role from Chief Strategic Scientific Officer. Dr. Duker, who has been part of the EyePoint team since 2020, has extensive experience in retinal disease and entrepreneurship. His leadership aims to enhance EyePoint's development of next-generation ophthalmic therapeutics, including the promising EYP-1901 for wet AMD. The company is excited about his ability to lead clinical and product development as it strives to address significant eye disorders.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will host a conference call on November 3, 2021, at 8:30 a.m. ET to discuss its Q3 2021 financial results and recent business developments. This call is part of the company's commitment to improving therapeutics for serious eye disorders, utilizing its proprietary Durasert® technology. EyePoint's pipeline includes EYP-1901, targeting wet age-related macular degeneration, alongside its commercial products, YUTIQ® and DEXYCU®.